Article

At the Morgan Stanley 23rd Annual Global Healthcare Conference, Livanova PLC presented a robust outlook, showcasing double-digit growth in its cardiopulmonary segment and strategic advancements in neuromodulation. The company addressed supply chain challenges while raising its full-year growth guidance and free cash flow expectations.

Key initiatives include launching the Ascend heart-lung machine in China and enhancing AI capabilities. Livanova is also expanding its presence in the obstructive sleep apnea market and pursuing reimbursement opportunities for its epilepsy and depression therapies.